Search clinical trials for: Pvs25-IMX313/Matrix-M1

Total 19 results

University of Oxford

Active, not recruiting

Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine

Malaria, Vivax

United Kingdom
University of Oxford

Terminated

VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine

Malaria,Falciparum

United Kingdom
University of Oxford
Ifakara Health Institute

Recruiting

Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.

Malaria,Falciparum

Tanzania
University of Oxford

Completed

A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313

Malaria

United Kingdom
European Vaccine Initiative
University of Oxford; Malaria Research and Training Center, Bamako, Mali

Not yet recruiting

Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali

Healthy Women of Child Bearing Potential
University of Oxford

Recruiting

Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1

Malaria, Vivax

United Kingdom
University of Oxford

Completed

A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1

Malaria

United Kingdom
University of Oxford

Completed

A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant

Malaria

Burkina Faso
Novavax
Department of Health and Human Services

Completed

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Covid19 | SARS-CoV Infection

United States, Mexico, Puerto Rico
Novavax
Department of Health and Human Services

Completed

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

Influenza (Pandemic)

United States
Novavax

Active, not recruiting

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years (COVID-19)

COVID-19

Spain, United States, South Africa, Mexico, United Kingdom, Philippines, Colombia, Dominican Republic, Guatemala, Honduras
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

EBV | Epstein-Barr Virus Infection | Infectious Mononucleosis

United States
University of Oxford

Completed

A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP

Malaria

United Kingdom
Novavax

Completed

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine

Covid19 | SARS-CoV Infection

Australia
National Institute of Allergy and Infectious Diseases...

Recruiting

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Epstein-Barr Virus Infection | Infectious Mononucleosis | Herpesvirus

United States
Novavax
Bill and Melinda Gates Foundation

Completed

A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults

COVID-19 | SARS-CoV-2 Infection

South Africa
Novavax

Completed

A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

COVID-19 | SARS-CoV-2 Infection

United Kingdom
Novavax

Completed

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Respiratory Syncytial Viruses

Australia
Lv Yingjuan

Completed

Comparison of Vitamin D Status and Vitamin D Receptor Polymorphisms in Patients With High Myopia and Primary Open-angle Glaucoma

Vitamin D Deficiency | High Myopia | Primary Open-angle Glaucoma | Vitamin D Receptor Polymorphisms

China

3

Subscribe